Windtree Therapeutics Holds Special Meeting of Stockholders, Receives Approval for Amendments – A Look Inside the 8-K Filing

Windtree Therapeutics, Inc. recently held a virtual Special Meeting of Stockholders on February 3, 2025. At this meeting, the company reported final voting results for proposals outlined in the Definitive Proxy Statement filed on January 8, 2025, with the U.S. Securities and Exchange Commission.

One of the key proposals included was the approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the company’s outstanding common stock by a ratio between 1-for-5 and 1-for-50. The outcome of the voting showed 2,504,535 votes for, 1,752,258 votes against, and 103,627 abstentions, with no broker non-votes.

Another significant proposal was the approval of an amendment to the Amended and Restated Windtree Therapeutics, Inc. 2020 Equity Incentive Plan to increase the number of shares authorized for issuance under the plan from 41,010 shares to 1,141,010 shares. The results revealed 586,282 votes for, 1,323,734 votes against, 69,270 abstentions, and 2,381,134 broker non-votes.

The meeting was crucial in determining the company’s direction regarding operational modifications and incentive plan adjustments. Windtree Therapeutics has been responsive to its shareholders’ input and engaged in transparent decision-making processes.

Investors and stakeholders will be closely monitoring Windtree Therapeutics as it progresses with the implementation of these approved proposals, gauging potential impacts on the company’s strategic and financial outlook.

This concludes the summary of the 8-K filing by Windtree Therapeutics, Inc. If there are any further developments, MarketBeat will keep investors informed.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Windtree Therapeutics’s 8K filing here.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.